Amicus Therapeutics (NASDAQ: FOLD)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.250 | -0.300 | -0.0500 | ||||
REV | 77.130M | 78.715M | 1.585M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Amicus Therapeutics (NASDAQ: FOLD) through any online brokerage.
Other companies in Amicus Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Karuna Therapeutics (NASDAQ:KRTX), Cerevel Therapeutics Hldg (NASDAQ:CERE), Sage Therapeutics (NASDAQ:SAGE) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for Amicus Therapeutics (NASDAQ: FOLD) was reported by SVB Leerink on Thursday, February 24, 2022. The analyst firm set a price target for 14.00 expecting FOLD to rise to within 12 months (a possible 29.63% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Amicus Therapeutics (NASDAQ: FOLD) is $10.8 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Amicus Therapeutics.
Amicus Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Amicus Therapeutics.
Amicus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.